Editas Medicine Wins CRISPR Patent Dispute with Broad Institute.

Editas Medicine's exclusive licenses to Broad's CRISPR/Cas9 patents have been reaffirmed by the USPTO, strengthening the company's confidence in its patent position and efforts to advance in vivo gene editing programs, including its experimental therapy EDIT-401 for cholesterol-lowering. The decision comes after a long-running dispute with the University of California and Emmanuelle Charpentier, which still has the right to appeal. Editas Medicine's broader patent portfolio remains intact.